Spots Global Cancer Trial Database for non small cell lung cancer
Every month we try and update this database with for non small cell lung cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | NCT03201146 | Lung Cancer Non Small Cell ... Combination Che... Apatinib | Apatinib AP or AC Apatinib 250mg Apatinib 500mg Apatinib 750mg | 18 Years - 70 Years | West China Hospital | |
| TEIPP Immunotherapy in Patients With NSCLC | NCT05898763 | Non Small Cell ... | TEIPP24 (LRPAP7... | 18 Years - | Erasmus Medical Center | |
| Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | NCT00798720 | Carcinoma, Non ... | vorinostat bortezomib | 18 Years - | University of Wisconsin, Madison | |
| Study of Use of CTC in NSCLC | NCT01990651 | Non Small Cell ... Chronic Obstruc... | 18 Years - | University of Virginia | ||
| Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） | NCT03735264 | Non Small Cell ... | Anlotinib Hydro... | 18 Years - 75 Years | The Affiliated Hospital of Qingdao University | |
| Alvopem® (Pemetrexed) Safety Assessment | NCT04843007 | Non Small Cell ... Malignant Pleur... | Pemetrexed | - | NanoAlvand | |
| Lung Heart Rate Variability | NCT03674450 | Non Small Cell ... | Heart Rate Vari... | 18 Years - 70 Years | Abramson Cancer Center at Penn Medicine | |
| A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer | NCT01237171 | NSCLC Non Small Cell ... | Cesium-131 Brac... | - | IsoRay Medical, Inc. | |
| Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | NCT00234442 | Brain Neoplasms Non Small Cell ... | Iressa (Gefitin... | 18 Years - | AstraZeneca | |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | NCT00714246 | Non Small Cell ... | Bortezomib Carboplatin Docetaxel | 18 Years - 90 Years | Milton S. Hershey Medical Center | |
| A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | NCT06142617 | Non Small Cell ... Immune Checkpoi... EGFR Exon 21 Mu... | Pembrolizumab, ... Osimertinib | 18 Years - | Peking Union Medical College Hospital | |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | NCT04383938 | Bladder Cancer Gastric Cancer Non Small Cell ... NSCLC Urothelial Carc... Advanced Solid ... | APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer | NCT05138900 | Non Small Cell ... | SBRT | 18 Years - | Roswell Park Cancer Institute | |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | NCT03425006 | Non Small Cell ... | Itacitinib Pembrolizumab | 18 Years - | University of Pennsylvania | |
| T790M Mutation Positive 2nd Line STandard of cAre Registry | NCT02368990 | Non Small Cell ... | 18 Years - | AstraZeneca | ||
| Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression | NCT01998061 | Non Small Cell ... | EGFR tyrosine k... EGFR tyrosine k... | 18 Years - 75 Years | Zhejiang University | |
| BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | NCT01562028 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery | NCT05251805 | Non Small Cell ... | Blood, bone mar... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer | NCT00192036 | Non Small Cell ... | gemcitabine cisplatin radiation | 18 Years - | Eli Lilly and Company | |
| Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB | NCT04197076 | Non Small Cell ... | anti-PD-1 or an... EGFR-TKI, ALK i... investigator de... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | NCT03474497 | Non Small Cell ... Metastatic Mela... Metastatic Rena... Head and Neck S... | IL-2 Pembrolizumab Radiotherapy | 18 Years - | University of California, Davis | |
| Low Volume High Intensity Interval Training in Operated Lung Cancer Patients | NCT05837429 | Lung Cancer Non Small Cell ... | Low Volume High... Aerobic Exercis... | 18 Years - 80 Years | Hacettepe University | |
| Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer | NCT05452005 | Lung Cancer Lung Cancer Met... Brain Metastase... Non Small Cell ... | [18F]-αvβ6-BP | 18 Years - | University of California, Davis | |
| Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. | NCT05102110 | Non Small Cell ... Gastric Adenoca... Pancreatic Canc... Gall Bladder Ca... Bladder Cancer | Oricol Test | 18 Years - 99 Years | Origin Sciences | |
| A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | NCT05180422 | Non Small Cell ... | AMG 510 MVASI | 18 Years - | Criterium, Inc. | |
| Erlotinib and Sunitinib in NSCLC | NCT00581789 | Non Small Cell ... | erlotinib, suni... | 18 Years - | University of Wisconsin, Madison | |
| Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | NCT00753909 | Non Small Cell ... | Carboplatin Bevacizumab Paclitaxel | 18 Years - | Hellenic Oncology Research Group | |
| Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) | NCT00462995 | Non Small Cell ... | Erlotinib Erlotinib | 18 Years - 95 Years | University Health Network, Toronto | |
| Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC) | NCT00419042 | Non Small Cell ... | TARCEVA Gemzar | 65 Years - | Groupe Francais De Pneumo-Cancerologie | |
| A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer | NCT01237171 | NSCLC Non Small Cell ... | Cesium-131 Brac... | - | IsoRay Medical, Inc. | |
| EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC) | NCT00879866 | Lung Cancer Non Small Cell ... | EMD 521873 | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| NM404 as an Imaging Agent in Patients With NSCLC | NCT00582283 | Non Small Cell ... | I124-NM404 | 18 Years - | University of Wisconsin, Madison | |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION | NCT04262375 | Non Small Cell ... Renal Cell Carc... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | NCT00891579 | Non Small Cell ... | Pemetrexed (Ali... Gefitinib (IRES... | 18 Years - 80 Years | Chinese Society of Lung Cancer | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Evaluation of NSCLC Patients' Oxygen Uptake On-kinetics at Cycle-ergometer During Prehabilitation | NCT04041297 | Non Small Cell ... | Preoperative Pu... | 18 Years - | ADIR Association | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | NCT05460481 | Non Small Cell ... | Anlotinib Plus ... | 18 Years - 75 Years | Hunan Cancer Hospital | |
| Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients | NCT01749072 | Non-small Cell ... Effects of Chem... | Gefitinib group Vinorelbine, If... | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | NCT00252798 | Non Small Cell ... | Gefitinib Carboplatin Paclitaxel Radiation | 18 Years - | AstraZeneca | |
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors | NCT03946007 | Melanoma Non Small Cell ... | 18 Years - | University Medical Center Groningen | ||
| Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.) | NCT06180005 | Non Small Cell ... | - | Centro di Riferimento Oncologico - Aviano | ||
| Phase II Lung Metcore - Preoperative Metformin for Lung Cancer | NCT03086733 | Non Small Cell ... Lung Cancer | Metformin | 18 Years - 90 Years | University Health Network, Toronto | |
| Tumor Treating Fields for Locally Advanced NSCLC | NCT06124118 | Non Small Cell ... | carboplatin che... NovoTTF-200T (T... Durvalumab | 22 Years - | University of Utah | |
| Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) | NCT01355484 | Muscle Wasting Non Small Cell ... | GTx-024 placebo | 30 Years - | GTx | |
| Pembrolizumab + Idelalisib for Lung Cancer Study | NCT03257722 | Non Small Cell ... Metastasis Recurrence | Pembrolizumab Idelalisib | 18 Years - | Augusta University | |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | NCT01090830 | Non-Small-Cell ... | Belinostat, car... | 18 Years - | Holy Cross Hospital, Florida | |
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC | NCT00492206 | Non Small Cell ... | Cetuximab | 18 Years - | University of Pittsburgh | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment | NCT03706625 | Non Hodgkin Lym... Non Small Cell ... Glioma | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. | NCT03968419 | Non-small Cell ... | Canakinumab Pembrolizumab | 18 Years - | Novartis | |
| Vapor Ablation for Localized Cancer Lesions | NCT03514329 | Non Small Cell ... Metastatic Lung... Lung Cancer | Bronchoscopic T... | 18 Years - | Uptake Medical Technology, Inc. | |
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | NCT04919811 | Non Small Cell ... | Taletrectinib | 18 Years - | AnHeart Therapeutics Inc. | |
| Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer | NCT00460551 | Non Small Cell ... | Zalutumumab Induction chemo... Radiotherapy | 18 Years - | Genmab | |
| A Study of Personalized Neoantigen Cancer Vaccines | NCT03794128 | Non Small Cell ... Colorectal Canc... Gastroesophagea... Urothelial Carc... Pancreatic Duct... | Blood collectio... Blood collectio... | 18 Years - | Gritstone bio, Inc. | |
| Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | NCT04099836 | Non Small Cell ... | Atezolizumab Bevacizumab | 18 Years - | Duke University | |
| Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | NCT04726215 | Non Small Cell ... | [18F]F AraG | 18 Years - | CellSight Technologies, Inc. | |
| A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | NCT04636593 | Non Small Cell ... Stage III NSCLC EGFR Activating... | Almonertinib | 18 Years - | First People's Hospital of Hangzhou | |
| Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | NCT05845671 | Lung Cancer Non Small Cell ... | Amivantamab 105... Amivantamab 140... Amivantamab (to... Amivantamab (to... | 18 Years - 90 Years | University of Colorado, Denver | |
| Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | NCT04786093 | Non Small Cell ... | Stereotactic ra... Durvalumab | 18 Years - | University of Texas Southwestern Medical Center | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 | NCT04604470 | NSCLC Stage IV Lung Cancer Non Small Cell ... Metastatic Canc... | Decision tool | 18 Years - | Maastricht University | |
| ENCOrafenib With Binimetinib in bRAF NSCLC | NCT04526782 | Non Small Cell ... BRAF V600E | Encorafenib 75 ... Binimetinib 15 ... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease | NCT01784549 | Non Small Cell ... | Cisplatin Docet... | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Combined Application of EBUS and EUS in Lung Cancer | NCT01385111 | Non Small Cell ... | EUS-B-FNA follo... EBUS-TBNA follo... | 18 Years - | National Cancer Center, Korea | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | NCT04943029 | Non Small Cell ... | Carrelizumab Pemetrexed (Non... Carboplatin Surgery | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | NCT00684385 | Non Small Cell ... Cancer of the H... | ZD1839 | 18 Years - 130 Years | AstraZeneca | |
| Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence. | NCT06163846 | Non Small Cell ... | Assess the role... | 18 Years - 70 Years | IRCCS San Raffaele | |
| Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer | NCT00956280 | Non Small Cell ... | 18 Years - | AstraZeneca | ||
| Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis | NCT00762346 | Non Small Cell ... Bone Metastases High NTX Level | zometa | 18 Years - | Sun Yat-sen University | |
| Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | NCT05245500 | Mesothelioma Non Small Cell ... Malignant Perip... Solid Tumor Pancreatic Aden... Advanced Solid ... | MRTX1719 | 18 Years - | Mirati Therapeutics Inc. | |
| SCION: SABR and Checkpoint Inhibition Of NSCLC | NCT04944173 | Non Small Cell ... Carcinoma, Non-... Non-small Cell ... Lung Cancer Lung Cancer Sta... Lung Adenocarci... Lung Squamous C... | Durvalumab Stereotactic Bo... Circulating Tum... | 18 Years - | University of British Columbia | |
| Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | NCT02448251 | Non Small Cell ... | AC0010MA | 18 Years - | ACEA Therapeutics, Inc. | |
| A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors | NCT04440735 | Advanced Solid ... Non Small Cell ... Colorectal Canc... | DSP107 Atezolizumab | 18 Years - | Kahr Medical | |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | NCT01090830 | Non-Small-Cell ... | Belinostat, car... | 18 Years - | Holy Cross Hospital, Florida | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
